文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

血管加压素受体激动剂在脓毒性休克患者中的疗效与安全性:荟萃分析与试验序贯分析

The effects and safety of vasopressin receptor agonists in patients with septic shock: a meta-analysis and trial sequential analysis.
PubMed 文献 · Crit Care · 2019-03-14
一句话结论荟萃分析显示血管加压素受体激动剂可能降低脓毒性休克患者死亡率(RR 0.92),但数字缺血风险显著增加(RR 4.85),须加以考虑。

该荟萃分析检索 PubMed、EMBASE 和 Cochrane 图书馆,纳入 20 项评估血管加压素受体激动剂在脓毒性休克患者中疗效的随机对照试验。主要终点为死亡率,结果显示血管加压素受体激动剂使用与死亡率降低相关(RR 0.92;95%CI 0.84–0.99;I²=0%)。ICU 住院时间(MD -0.08,95%CI -0.68–0.52)和机械通气时长(MD -0.58,95%CI -1.47–0.31)无显著影响;总不良事件无显著差异(RR 1.28,95%CI 0.87–1.90),但数字缺血风险显著增加(RR 4.85,95%CI 2.81–8.39)。结论认为血管加压素可能降低脓毒性休克患者死亡率,但须考虑数字缺血风险增加。

要点

  • 20 项 RCT 的荟萃分析显示,血管加压素受体激动剂与脓毒性休克患者死亡率降低相关(RR 0.92;95%CI 0.84–0.99;I²=0%)。
  • 血管加压素受体激动剂显著增加数字缺血风险(RR 4.85;95%CI 2.81–8.39;I²=26%),床旁须警惕。
  • 总不良事件两组无显著差异(RR 1.28;95%CI 0.87–1.90;I²=57%)。
  • ICU 住院时间(MD -0.08,95%CI -0.68–0.52;I²=0%)和机械通气时长(MD -0.58,95%CI -1.47–0.31;I²=57%)无显著影响。
  • 心血管事件、心律失常、肠系膜缺血、腹泻、脑血管事件及低钠血症两组均无统计学差异。

适用人群与场景

  • 脓毒性休克患者(纳入随机对照试验的研究人群)。

红旗征与不能漏的情况

  • 数字缺血风险显著增加(RR 4.85;95%CI 2.81–8.39;I²=26%),使用血管加压素受体激动剂时须考虑。

研究设计与关键结果

  • 研究类型:荟萃分析与试验序贯分析,纳入 20 项随机对照试验。
  • 主要终点死亡率:血管加压素受体激动剂组较对照组降低(RR 0.92;95%CI 0.84–0.99;I²=0%)。
  • ICU 住院时间:无显著影响(MD -0.08;95%CI -0.68–0.52;I²=0%)。
  • 机械通气时长:无显著影响(MD -0.58;95%CI -1.47–0.31;I²=57%)。
  • 总不良事件:两组无显著差异(RR 1.28;95%CI 0.87–1.90;I²=57%)。
  • 数字缺血:血管加压素受体激动剂组风险显著增加(RR 4.85;95%CI 2.81–8.39;I²=26%)。
  • 心血管事件(RR 0.91;95%CI 0.53–1.57;I²=1%)、心律失常(RR 0.77;95%CI 0.48–1.23;I²=23%)、肠系膜缺血(RR 0.83;95%CI 0.44–1.55;I²=0%)、腹泻(RR 2.47;95%CI 0.77–7.96;I²=49%)、脑血管事件(RR 1.36;95%CI 0.18–10.54;I²=0%)及低钠血症(RR 1.47;95%CI 0.84–2.55;I²=0%)两组均无统计学差异。
  • Egger 检验提示无显著发表偏倚(P=0.36)。

证据类型、等级与局限

  • 证据类型:荟萃分析与试验序贯分析(基于 20 项随机对照试验)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,血管加压素的使用可能降低脓毒性休克患者死亡率(RR 0.92;95%CI 0.84–0.99)。
  • 作者认为,必须考虑数字缺血风险增加(RR 4.85;95%CI 2.81–8.39)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The aim of this study was to evaluate the effects and safety of vasopressin receptor agonists in patients with septic shock.

METHODS: PubMed, EMBASE, and Cochrane library were searched for randomized controlled trials evaluating the effects of vasopressin receptor agonists in septic shock patients. Two reviewers performed literature selection, data extraction, and quality evaluation independently. The primary outcome was mortality. And secondary outcomes included intensive care unit (ICU) length of stay, duration of mechanical ventilation, and incidence of adverse events. In addition, a trial sequential analysis (TSA) was performed.

RESULTS: Twenty studies were eligible for meta-analysis. The results showed vasopressin receptor agonists use was associated with reduced mortality (relative risk (RR) 0.92; 95% confidence interval (CI) 0.84 to 0.99; I2 = 0%). Nevertheless, they had no significant effects on ICU length of stay (mean deviation (MD) - 0.08, 95% CI, - 0.68 to 0.52, I2 = 0%) and duration of mechanical ventilation (MD - 0.58, 95% CI - 1.47 to 0.31, I2 = 57%). Additionally, there was no significant difference in total adverse events between two groups (RR 1.28, 95% CI 0.87 to 1.90, I2 = 57%), but vasopressin receptor agonists administration could significantly increase the risk of digital ischemia (RR 4.85, 95% CI 2.81 to 8.39, I2 = 26%). Finally, there was no statistical difference of cardiovascular events (RR 0.91, 95% CI 0.53 to 1.57, I2 = 1%), arrhythmia (0.77, 95% CI 0.48 to 1.23, I2 = 23%), mesenteric ischemia (0.83, 95% CI 0.44 to 1.55, I2 = 0%), diarrhea (2.47, 95% CI 0.77 to 7.96, I2 = 49%), cerebrovascular events (1.36, 95% CI 0.18 to 10.54, I2 = 0%), and hyponatremia (1.47, 95% CI 0.84 to 2.55, I2 = 0%) between two groups. Egger's test showed there was no significant publication bias among studies (P = 0.36).

CONCLUSIONS: The use of vasopressin might result in reduced mortality in patients with septic shock. An increased risk of digital ischemia must be taken into account.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Jiang L, Sheng Y, Feng X, et al. The effects and safety of vasopressin receptor agonists in patients with septic shock: a meta-analysis and trial sequential analysis. Crit Care. 2019. PMID: 30871607. doi:10.1186/s13054-019-2362-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。